Your browser doesn't support javascript.
loading
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
Mattingly, Greg W; Haddad, Peter M; Tocco, Michael; Xu, Jane; Phillips, Debra; Pikalov, Andrei; Loebel, Antony.
Affiliation
  • Mattingly GW; Washington University School of Medicine, St. Louis, MO, USA.
  • Haddad PM; Hamad Medical Corporation, Doha, Qatar.
  • Tocco M; Clinical Professor of Psychiatry, Qatar University, Doha, Qatar.
  • Xu J; Honorary Professor of Psychiatry, University of Manchester, Manchester, UK.
  • Phillips D; Honorary Consultant Psychiatrist, GMMH NHS Foundation Trust, Manchester, UK.
  • Pikalov A; Sunovion Pharmaceuticals Inc., Fort Lee, NJ, 84 Waterford Dr, Marlborough, MA, 01752, USA. paladinmed@gmail.com.
  • Loebel A; Sunovion Pharmaceuticals Inc., Fort Lee, NJ, 84 Waterford Dr, Marlborough, MA, 01752, USA.
BMC Psychiatry ; 20(1): 199, 2020 05 05.
Article in En | MEDLINE | ID: mdl-32370778
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Risperidone / Metabolic Syndrome / Lurasidone Hydrochloride Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Language: En Journal: BMC Psychiatry Journal subject: PSIQUIATRIA Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Risperidone / Metabolic Syndrome / Lurasidone Hydrochloride Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Language: En Journal: BMC Psychiatry Journal subject: PSIQUIATRIA Year: 2020 Document type: Article Affiliation country: Country of publication: